Annual Reports

 
Quarterly Reports

 
8-K

 
Other

  • 6-K (Mar 12, 2018)
  • 6-K (Mar 9, 2018)
  • 6-K (Mar 5, 2018)
  • SC 13G (Feb 12, 2018)
  • 6-K (Jan 31, 2018)
  • SC 13G (Jan 8, 2018)
Intec Pharma Ltd. 6-K 2017

Documents found in this filing:

  1. 6-K
  2. Ex-99.1
  3. Graphic
  4. Graphic

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT of 1934

 

For the Month of August 2017

 

001-37521

(Commission File Number)

 

INTEC PHARMA LTD. 

(Translation of registrant’s name into English)

 

12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel 

(+972) (2) 586-4657 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover 

Form 20-F or Form 40-F.

 

Form 20-F ☒   Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________

 

 

 

 

EXPLANATORY NOTE

 

On August 3, 2017, Intec Pharma Ltd., issued a press release titled “Intec Pharma Reports Clinical Results from Phase I Trial of Accordion Pill for Cannabinoid Therapies.”

 

Copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference into the Company’s registration statements on Form S-8 (Files No. 333-209700 and No. 333-212801) and F-3 (Files No. 333-217189 and No. 333-218539).

 

2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  INTEC PHARMA LTD.
     
  By: /s/ Nir Sassi
    Name: Nir Sassi
    Title: Chief Financial Officer
     
 Date: August 3, 2017    

  

3 

 

 

EXHIBIT INDEX

 

Exhibit No. Description
   
99.1 Press Release, dated August 3, 2017

 

4 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki